Waterdrop Inc - WDH STOCK NEWS

Waterdrop (NYSE: WDH) has announced a strategic partnership with DeepSeek to enhance its AI-driven insurance ecosystem. The collaboration aims to transform traditional insurance services through advanced AI implementation. The company's AI Insurance Expert system now supports multi-modal interactions and can engage users for up to 50 minutes per session, outperforming entry-level human agents.

The company has also launched its Large-scale AI Model Insurance Quality Inspection Solution, which provides 100% coverage across all channels while reducing operational costs by over 50% compared to manual inspections. In 2024, Waterdrop introduced 174 tailored insurance products, representing more than 92% of its offerings, focusing on specific demographic segments including the elderly, expectant mothers, and individuals with chronic health conditions.

Waterdrop Inc. (NYSE: WDH) reported strong Q3 2024 financial results with net operating revenue of RMB 704.1 million. The company's net profit reached RMB 92.8 million, marking a 152.6% year-over-year increase and its eleventh consecutive profitable quarter. Operating expenses decreased by 6.9 percentage points to 47.9% of revenue.

The insurance business generated RMB 600.7 million in revenue with operating profit of RMB 123 million. First-year premiums grew 20.4% to RMB 2,041.8 million. The company's Medical Crowdfunding platform has raised RMB 66.3 billion for 3.32 million patients, while its Digital Clinical Trial Solution generated RMB 24.3 million in revenue, enrolling over 9,500 patients in 1,137 clinical trials.

Waterdrop Inc. (NYSE: WDH) reported strong Q3 2024 financial results with significant profitability improvement. Net profit reached RMB92.8 million, up 152.6% year-over-year. First-year premiums (FYP) grew 20.4% to RMB2,041.8 million, while net operating revenue increased 2.6% to RMB704.1 million.

The company's insurance business maintained an operating profit margin above 20%, with 14.8% quarter-over-quarter FYP growth. The medical crowdfunding platform expanded its reach, with 466 million people donating RMB66.3 billion to 3.32 million patients. The digital clinical trial solution showed 17.4% quarter-over-quarter growth, collaborating with 184 pharmaceutical companies and CROs.

By November 2024, Waterdrop had repurchased approximately 50.9 million ADSs and completed a second special cash dividend of US$7.3 million.

Allink Biotherapeutics has secured a $42 million Series A financing led by Lanchi Ventures, with participation from Yuanbio Venture Capital, Legend Capital, C&D Emerging Industry Equity Investment, and existing investors. The funding will support the global clinical development of lead candidates ALK201 and ALK202 through Phase 1 studies across Australia, the United States, and China. The company focuses on developing next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics for oncology and immunology applications. The proceeds will also fund portfolio expansion, technology platform development, and global footprint growth.

Waterdrop Inc. (NYSE: WDH), a technology platform focused on insurance and healthcare services, has scheduled its third quarter 2024 financial results announcement for December 11, 2024, before U.S. markets open. The management team will host a conference call at 7:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time) on the same day. The call will be available in both Chinese and English, with the English line being listen-only. Replay access will be available until December 18, 2024, and a webcast will be accessible on the company's investor relations website.

Waterdrop Inc. (NYSE: WDH) reported strong Q2 2024 results, with net profit rising 306.9% year-on-year to RMB 88.3 million. The company's net operating revenue reached RMB 676 million, marking its tenth consecutive profitable quarter. Operating expenses decreased by 12 percentage points to 45.1% of revenue. Waterdrop announced a second special cash dividend of $7.5 million and approved a new $50 million share repurchase program.

The insurance business generated RMB 573.8 million in revenue and RMB 123 million in operating profit. The Medical Crowdfunding platform has raised RMB 65.1 billion for 3.25 million patients. The company is also investing in AI technology, piloting its 'Waterdrop Guardian' large language model in various insurance scenarios.

Waterdrop (NYSE: WDH) announced its unaudited financial results for Q2 2024 and a special cash dividend.

Highlights:

• Net profit attributable to ordinary shareholders reached RMB88.3 million, a 306.9% YoY growth.
• Despite industry challenges, the first-year premiums (FYP) dropped 19.0% YoY to RMB1,778.6 million.
• Net operating revenue decreased by 0.4% YoY to RMB676.2 million.
• Insurance operating profit margin increased from 16.7% to 21.4% YoY.
• Crowdfunding service fees increased by 55.2% YoY to RMB69.3 million.
• Healthcare-related income fell 17.0% YoY but grew 4.2% QoQ.
• Net operating costs and expenses decreased by 13.4% YoY.
• Board approved a new share repurchase program of up to US$50 million and a special cash dividend of US$0.02 per ADS.
• Cash and cash equivalents stood at RMB2,933.3 million as of June 30, 2024.

Waterdrop Inc. (NYSE: WDH), a leading technology platform for insurance and healthcare services, has announced it will report its unaudited financial results for the second quarter ended June 30, 2024, before U.S. markets open on September 4, 2024. The company will hold a conference call on the same day at 8:00 AM U.S. Eastern Time to discuss the financial results.

The earnings call will offer both Chinese and English interpretation lines, with the English line in listen-only mode. Participants are advised to dial in 15 minutes before the call starts. Telephone replays will be available until September 11, 2024. Additionally, live and archived webcasts of the conference call will be accessible on the company's investor relations website.

On June 5, 2024, Waterdrop (NYSE: WDH) reported Q1 2024 financial results. The company achieved revenue of RMB 704.7 million, a 16.3% year-on-year increase, and a net profit of RMB 80.6 million, up 62.2%. This marks nine consecutive profitable quarters. Operating expenses decreased to 46.4% of revenue. The insurance business saw a 13.1% increase in revenue to RMB 607 million, with life insurance representing 56.4% of the long-term product mix. Waterdrop Medical Crowdfunding raised RMB 63.8 billion, despite an operating loss of RMB 32.2 million. The company also saw 7.3% growth in healthcare-related services revenue, reaching RMB 25.3 million.